Department of Anaesthesia, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
PLoS One. 2023 Aug 1;18(8):e0289177. doi: 10.1371/journal.pone.0289177. eCollection 2023.
Patient outcomes are influenced by many confounding factors peri-operatively, including the type of surgery, anaesthesia, transfusion, and immune competence. We have previously demonstrated (in-vitro) that compared to allogeneic blood transfusion (ABT), intraoperative cell salvage (ICS) improves immune competence. The peri-operative immune response is complex. Altered or impaired immune responses may predispose patients to develop adverse outcomes (i.e., post-operative wound infection, pneumonia, urinary tract infection etc.) Surgical patients may develop infection, even without the confirmed presence of a definite microbiological pathogen. With all these factors in mind it is important to consider changes in immune cell numbers (and sub-populations) and functional capacity during peri-operative transfusion.
In this TRIMICS-Cell (Transfusion Related Immune Modulation and Intraoperative Cell Salvage-Cell numbers) study (n = 17, October 2018-November 2019) we prioritized and analysed peri-operative changes in the number and proportions of immune cell populations and sub-populations (B cells (CD20+), NK (natural killer) cells (CD56+), monocytes (CD14+), T cells (total CD3+ and sub-populations: T helper cells (CD4+), cytotoxic T cells (CD8+), effector T cells (CD4+ CD127+), activated effector T cells (CD4+ CD25+ CD127+) and regulatory T cells (CD4+ CD25+ CD127-)), plasmacytoid dendritic cells (pDC; Lineage-, HLA-DR+, CD11c-, CD123+), classical dendritic cell (cDC) (Lineage-, HLA-DR+, CD11c+), and cDC activation (Lineage-, HLA-DR+, CD11c+), co-stimulatory/adhesion molecules and pDC (CD9+, CD38+, CD80+, CD83+, CD86+, CD123+). Firstly we analysed the whole cohort of study patients and secondly according to the relevant transfusion modality (i.e., three study groups: those who received no transfusion, received ICS only (ICS), or both ICS and allogeneic packed red blood cells (pRBC) (ICS&RBC)), during major orthopaedic surgery.
For the whole study cohort (all patients), changes in immune cell populations were significant: leucocytes and specifically neutrophils increased post-operatively, returning towards pre-operative numbers by 48h post-operatively (48h), and lymphocytes reduced post-operatively returning to pre-operative numbers by 48h. When considering transfusion modalities, there were no significant peri-operative changes in the no transfusion group for all immune cell populations studied (cell numbers and proportions (%)). Significant changes in cell population numbers (i.e., leucocytes, neutrophils and lymphocytes) were identified in both transfused groups (ICS and ICS&RBC). Considering all patients, changes in immune cell sub-populations (NK cells, monocytes, B cells, T cells and DCs) and functional characteristics (e.g., co-stimulation markers, adhesion, activation, and regulation) were significant peri-operatively and when considering transfusion modalities. Interestingly DC numbers and functional capacity were specifically altered following ICS compared to ICS&RBC and pDCs were relatively preserved post-operatively following ICS.
A transient peri-operative alteration with recovery towards pre-operative numbers by 48h post-surgery was demonstrated for many immune cell populations and sub-populations throughout. Immune cell sub-populations and functional characteristics were similar peri-operatively in those who received no transfusion but changed significantly following ICS and ICS&RBC. Interesting changes that require future study are a post-operative monocyte increase in the ICS&RBC group, changes in cDC considering transfusion modalities, and possibly preserved pDC numbers post-operatively following ICS. Future studies to assess changes in immune cell sub-populations, especially during peri-operative transfusion, while considering post-operative adverse outcomes, is recommended.
患者的预后受到围手术期许多混杂因素的影响,包括手术类型、麻醉、输血和免疫功能。我们之前已经证明(在体外)与异体输血(ABT)相比,术中细胞回收(ICS)可改善免疫功能。围手术期的免疫反应是复杂的。改变或受损的免疫反应可能使患者易发生不良后果(即术后伤口感染、肺炎、尿路感染等)。外科患者可能会发生感染,即使没有确定的微生物病原体存在。考虑到所有这些因素,在围手术期输血期间,重要的是要考虑免疫细胞数量(和亚群)和功能能力的变化。
在这项 TRIMICS-Cell(输血相关免疫调节和术中细胞回收-细胞数量)研究(n = 17,2018 年 10 月至 2019 年 11 月)中,我们优先考虑并分析了围手术期免疫细胞群体和亚群数量和比例的变化(B 细胞(CD20+)、NK(自然杀伤)细胞(CD56+)、单核细胞(CD14+)、T 细胞(总 CD3+和亚群:辅助 T 细胞(CD4+)、细胞毒性 T 细胞(CD8+)、效应 T 细胞(CD4+ CD127+)、活化效应 T 细胞(CD4+ CD25+ CD127+)和调节性 T 细胞(CD4+ CD25+ CD127-))、浆细胞样树突状细胞(pDC;谱系-,HLA-DR+,CD11c-,CD123+)、经典树突状细胞(cDC)(谱系-,HLA-DR+,CD11c+)和 cDC 活化(谱系-,HLA-DR+,CD11c+)、共刺激/粘附分子和 pDC(CD9+,CD38+,CD80+,CD83+,CD86+,CD123+)。首先,我们分析了整个研究患者队列,其次根据相关输血方式(即,三个研究组:未输血、仅接受 ICS(ICS)或同时接受 ICS 和异体浓缩红细胞(pRBC)(ICS&RBC)),在大型骨科手术中进行分析。
对于整个研究队列(所有患者),免疫细胞群体的变化是显著的:白细胞特别是中性粒细胞术后增加,术后 48 小时恢复到术前数量(48h),淋巴细胞术后减少,术后 48 小时恢复到术前数量。当考虑输血方式时,未输血组所有研究的免疫细胞群体(细胞数量和比例(%))均无显著围手术期变化。在 ICS 和 ICS&RBC 两组中,均发现细胞群体数量(即白细胞、中性粒细胞和淋巴细胞)的显著变化。考虑到所有患者,免疫细胞亚群(NK 细胞、单核细胞、B 细胞、T 细胞和 DC)和功能特征(例如,共刺激标志物、粘附、激活和调节)在围手术期以及考虑输血方式时都发生了显著变化。有趣的是,与 ICS&RBC 相比,ICS 后 DC 数量和功能能力发生了特异性改变,并且 ICS 后 pDC 数量相对保持不变。
在整个过程中,许多免疫细胞群体和亚群都表现出短暂的围手术期改变,恢复到术后 48 小时的术前数量。在未输血但在 ICS 和 ICS&RBC 后发生显著变化的患者中,免疫细胞亚群和功能特征在围手术期相似。有趣的变化需要进一步研究,包括 ICS&RBC 组术后单核细胞增加、考虑输血方式的 cDC 变化以及 ICS 后可能保持不变的 pDC 数量。建议未来的研究评估围手术期输血期间免疫细胞亚群的变化,特别是在考虑术后不良后果的情况下。